GKOSGlaukos Corporation

Filed with the SEC on October 28, 2026 | Form 10-Q | Q3 FY2026

Note: StockWatch initiated coverage on Glaukos on September 28, 2026. This report covers the new financial disclosures only and does not restate or update that prior assessment.

---

What Happened

Glaukos Corporation filed its Form 10-Q for the third quarter of fiscal year 2026 with the SEC on October 28, 2026. The company reported revenue of $364.3 million for the quarter, alongside a net loss of $54.0 million (basic and diluted EPS of -$0.95) and an operating loss of $59.7 million. The quarterly filing is material because it provides the first comprehensive look at Glaukos's financial position since StockWatch's initiation of coverage in late September.

---

Why It Matters

For investors tracking Glaukos, the headline revenue figure of $364.3 million in a single quarter represents a significant operational scale, underscoring the company's continued commercial momentum in its ophthalmic surgical product lines. However, the persistent operating loss — -$59.7 million — and net loss of -$54.0 million serve as a clear reminder that the company is still investing heavily and has not yet translated its top-line growth into bottom-line profitability. Key near-term considerations include:

• Revenue strength: $364.3M in quarterly revenue demonstrates meaningful market penetration and demand for Glaukos's products.
• Profitability gap: The operating loss of -$59.7M signals that operating expenses continue to outpace revenue generation at the earnings level.
• EPS impact: A basic and diluted loss of -$0.95 per share quantifies the per-share cost of current investment and spending levels.
• Share price reaction: The stock is up +28.65% on the day of this report, suggesting the market interpreted these results — or accompanying guidance and commentary in the full filing — as more favorable than prior expectations.

---

Analysis

The juxtaposition of robust quarterly revenue ($364.3M) against a continued operating loss (-$59.7M) is the defining tension in this filing. The market's sharp positive reaction — shares rising more than 28% — suggests that investors may be focusing on the revenue trajectory rather than near-term profitability metrics, or that the full filing contained forward-looking disclosures (such as guidance revisions or pipeline updates) that the structured XBRL data alone does not capture. This report is grounded solely in the official XBRL-reported figures; readers should review the complete 10-Q filing directly for any qualitative commentary, guidance, or segment breakdowns that may be driving today's price action.

It is also worth noting that Glaukos's operating loss structure is not new — the company has been in an investment-heavy phase — but the scale of revenue at $364M per quarter indicates the business has grown substantially. Whether operating leverage begins to improve in coming quarters is the critical variable to watch. Analysts and investors should monitor the trajectory of operating expenses relative to revenue in subsequent filings.

---

Disclaimer

This report is a news and informational summary of a publicly filed SEC disclosure. It does not constitute investment advice, a recommendation to buy or sell any security, or a research rating of any kind. All financial figures cited are sourced exclusively from the official XBRL data accompanying Glaukos Corporation's Form 10-Q filed October 28, 2026. Past performance and current disclosures are not guarantees of future results. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.

Existing Coverage

StockWatch has full coverage on GKOS, published 2026-09-28. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-28. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1192448/000119312526436400/gkos-20260930.htm